Emerging drugs for the treatment of angina pectoris

References

• Beltrame JF, Crea F, Kaski JC, et al. The who, what, why, when, how and where of vasospastic angina. Circ J. 2016;80(2):289–298.
   PubMed Web of Science ®Google Scholar
• Freedman SB, Richmond DR, Kelly DT. Clinical studies of patients with coronary spasm. Am J Cardiol. 1983;52(2):67A–71A.
   PubMed Web of Science ®Google Scholar
• Cocco G, Jerie P. Angina pectoris in patients without flow-limiting coronary artery disease (cardiac syndrome X). A forest of a variety of trees. Cardiol J. 2015;22(6):605–612.
   PubMed Web of Science ®Google Scholar
• Ahn JH, Kim SM, Park SJ, et al. Coronary microvascular dysfunction as a mechanism of angina in severe as: prospective adenosine-stress CMR study. J Am Coll Cardiol. 2016;67(12):1412–1422.
   PubMed Web of Science ®Google Scholar
• Nakahashi T, Naka M, Shiotani I, et al. Vasospastic angina pectoris associated with apical hypertrophic cardiomyopathy. Intern Med. 1995;34(5):436–440.
   PubMed Web of Science ®Google Scholar
• Suzuki N, Seto S, Koide Y, et al. Coexistence of familial hypertrophic cardiomyopathy and vasospastic angina pectoris in two brothers. Jpn Heart J. 2003;44(5):775–782.
   PubMedGoogle Scholar
• Di Fiore DP, Beltrame JF. Chest pain in patients with ‘normal angiography’: could it be cardiac? Int J Evid Based Healthc. 2013;11(1):56–68.
   PubMedGoogle Scholar
• Munzel T, Steven S, Daiber A. Organic nitrates: update on mechanisms underlying vasodilation, tolerance and endothelial dysfunction. Vascul Pharmacol. 2014;63(3):105–113.
   PubMed Web of Science ®Google Scholar
• Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a veterans administration cooperative study. N Engl J Med. 1986;314(24):1547–1552.
   PubMed Web of Science ®Google Scholar
• Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351(20):2049–2057.
   PubMed Web of Science ®Google Scholar
• Boden WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Eng J Med. 2007;356(15):1503–1516.
   PubMed Web of Science ®Google Scholar
• Cheng DC, Jiang MT, Asokumar B, et al. Comparison of nifedipine and metoprolol on collateral coronary blood flow in a swine model of chronic coronary obstruction and acute ischaemia during isoflurane anaesthesia. Can J Anaesth. 1996;43(2):160–168.
   PubMed Web of Science ®Google Scholar
• Yokoyama M, Koizumi T, Fujitani K, et al. Adverse response to nifedipine in unstable angina pectoris. Chest. 1982;81(5):646–648.
   PubMed Web of Science ®Google Scholar
• Kezerashvili A, Marzo K, De Leon J. Beta blocker use after acute myocardial infarction in the patient with normal systolic function: when is it “ok” to discontinue? Curr Cardiol Rev. 2012;8(1):77–84.
   PubMedGoogle Scholar
• Poirier L, Tobe SW. Contemporary use of beta-blockers: clinical relevance of subclassification. Can J Cardiol. 2014;30(5 Suppl):S9–S15.
   PubMed Web of Science ®Google Scholar
• Randle PJ, Garland PB, Hales CN, et al. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963;1(7285):785–789.
   PubMed Web of Science ®Google Scholar
• Beadle RM, Frenneaux M. Modification of myocardial substrate utilisation: a new therapeutic paradigm in cardiovascular disease. Heart. 2010;96(11):824–830.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med. 2000;342(3):145–153.
   PubMed Web of Science ®Google Scholar
• Chow BS, Allen TJ. Angiotensin II type 2 receptor (AT2R) in renal and cardiovascular disease. Clin Sci (Lond). 2016;130(15):1307–1326.
   PubMed Web of Science ®Google Scholar
• Sverdlov AL, Chan WPA, Procter NEK, et al. Reciprocal regulation of NO signaling and TXNIP expression in humans: impact of aging and ramipril therapy. Int J Cardiol. 2013;168(5):4624–4630.
   PubMed Web of Science ®Google Scholar
• Simko F, Simko J, Fabryova M. ACE-inhibition and angiotensin II receptor blockers in chronic heart failure: pathophysiological consideration of the unresolved battle. Cardiovasc Drugs Ther. 2003;17(3):287–290.
   PubMedGoogle Scholar
• Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial–the losartan heart failure survival study ELITE II. Lancet. 2000;355(9215):1582–1587.
   PubMed Web of Science ®Google Scholar
• Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal trial in myocardial infarction with angiotensin II antagonist losartan. Lancet. 2002;360(9335):752–760.
   PubMed Web of Science ®Google Scholar
• Bussmann WD, Goerke S, Schneider W, et al. [Angiotensin-converting enzyme inhibitors in angina pectoris]. Dtsch Med Wochenschr. 1988;113(14):548–550.
   PubMed Web of Science ®Google Scholar
• Antonopoulos AS, Margaritis M, Shirodaria C, et al. Translating the effects of statins: from redox regulation to suppression of vascular wall inflammation. Thromb Haemost. 2012;108(5):840–848.
   PubMed Web of Science ®Google Scholar
• Deanfield JE, Sellier P, Thaulow E, et al. Potent anti-ischaemic effects of statins in chronic stable angina: incremental benefit beyond lipid lowering? Eur Heart J. 2010;31(21):2650–2659.
   PubMed Web of Science ®Google Scholar
• Lee L, Horowitz J, Frenneaux M. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur Heart J. 2004;25(8):634–641.
   PubMed Web of Science ®Google Scholar
• Ashrafian H, Horowitz JD, Frenneaux MP. Perhexiline. Cardiovasc Drug Rev. 2007;25(1):76–97.
   PubMed Web of Science ®Google Scholar
• Forbes GB, Rake MO, Taylor DJ. Liver damage due to perhexiline maleate. J Clin Pathol. 1979;32(12):1282–1285.
   PubMed Web of Science ®Google Scholar
• Lewis D, Wainwright HC, Kew MC, et al. Liver damage associated with perhexiline maleate. Gut. 1979;20(3):186–189.
   PubMed Web of Science ®Google Scholar
• Pieterse AS, Rowland R, Dunn D. Perhexiline maleate induced cirrhosis. Pathology. 1983;15(2):201–203.
   PubMed Web of Science ®Google Scholar
• Goble AJ, Horowitz JD. Perhexilene neuropathy: a report of two cases. Aust N Z J Med. 1984;14(3):279.
   PubMedGoogle Scholar
• Horowitz JD, Sia ST, Macdonald PS, et al. Perhexiline maleate treatment for severe angina pectoris–correlations with pharmacokinetics. Int J Cardiol. 1986;13(2):219–229.
   PubMed Web of Science ®Google Scholar
• Phuong, H, Choi BY, Chong CR, et al. Can perhexiline be utilized without long-term toxicity? A clinical practice audit. Ther Drug Monit. 2016; 38 (1): 73–8.
   PubMed Web of Science ®Google Scholar
• Kennedy JA, Unger SA, Horowitz JD. Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem Pharmacol. 1996;52(2):273–280.
   PubMed Web of Science ®Google Scholar
• Kennedy JA, Beck-Oldach K, McFadden-Lewis K, et al. Effect of the anti-anginal agent, perhexiline, on neutrophil, valvular and vascular superoxide formation. Eur J Pharmacol. 2006;531(1–3):13–19.
   PubMed Web of Science ®Google Scholar
• Ngo, D.T, Drury NE, Pagano D, et al. How does perhexiline maleate modulate myocardial energetics and ameliorate redox stress? Circulation. 2011;124:A14461.
   Web of Science ®Google Scholar
• Lee L, Campbell R, Scheuermann-Freestone M, et al. Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation. 2005;112(21):3280–3288.
   PubMed Web of Science ®Google Scholar
• Abozguia K, Elliott P, McKenna W, et al. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation. 2010;122(16):1562–1569.
   PubMed Web of Science ®Google Scholar
• Unger SA, Robinson MA, Horowitz JD. Perhexiline improves symptomatic status in elderly patients with severe aortic stenosis. Aust NZ J Med. 1997;27(1):24–28.
   PubMedGoogle Scholar
• Australian medicines handbook. Adelaide: Australian Medicines Handbook Pty Ltd; 2015.
   Google Scholar
• Gould BJ, Amoah AG, Parke DV. Stereoselective pharmacokinetics of perhexiline. Xenobiotica. 1986;16(5):491–502.
   PubMed Web of Science ®Google Scholar
• Licari G, Sallustio BC, Somogyi AA, et al. The enantiomers of the myocardial metabolic agent perhexiline display divergent effets on hepatic energy metabolism and peripheral neural function in rats. Global Heart. 2014;9(Supplement 1):e272.
   Google Scholar
• Chong CR, Drury NE, Licari G, et al. Stereoselective handling of perhexiline: implications regarding accumulation within the human myocardium. Eur J Clin Pharmacol. 2015;71(12):1485–1491.
   PubMed Web of Science ®Google Scholar
• Kantor PF, Lucien A, Kozak R, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2000;86(5):580–588.
   PubMed Web of Science ®Google Scholar
• Kennedy JA, Horowitz JD. Effect of trimetazidine on carnitine palmitoyltransferase-1 in the rat heart. Cardiovasc Drugs Ther. 1998;12(4):359–363.
   PubMed Web of Science ®Google Scholar
• Peng S, Zhao M, Wan J, et al. The efficacy of trimetazidine on stable angina pectoris: a meta-analysis of randomized clinical trials. Int J Cardiol. 2014;177(3):780–785.
   PubMed Web of Science ®Google Scholar
• Fragasso G, Perseghin G, De Cobelli F, et al. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J. 2006;27(8):942–948.
   PubMed Web of Science ®Google Scholar
• Tuunanen H, Engblom E, Naum A, et al. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation. 2008;118(12):1250–1258.
   PubMed Web of Science ®Google Scholar
• Danchin N, Marzilli M, Parkhomenko A, et al. Efficacy comparison of trimetazidine with therapeutic alternatives in stable angina pectoris: a network meta-analysis. Cardiology. 2011;120(2):59–72.
   PubMed Web of Science ®Google Scholar
• Rosano GMC, Vitale C, Volterrani M. Pharmacological management of chronic stable angina: focus on ranolazine. Cardiovasc Drugs Ther. 2016.
   PubMed Web of Science ®Google Scholar
• Wimmer NJ, Stone PH. Anti-anginal and anti-ischemic effects of late sodium current inhibition. Cardiovasc Drugs Ther. 2013;27(1):69–77.
   PubMed Web of Science ®Google Scholar
• Clarke B, Wyatt KM, McCormack JG. Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: evidence for an indirect mechanism. J Mol Cell Cardiol. 1996;28(2):341–350.
   PubMed Web of Science ®Google Scholar
• Stone PH, Gratsiansky NA, Blokhin A, et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. 2006;48(3):566–575.
   PubMed Web of Science ®Google Scholar
• Kosiborod M, Arnold SV, Spertus JA, et al. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). J Am Coll Cardiol. 2013;61(20):2038–2045.
   PubMed Web of Science ®Google Scholar
• Willoughby SR, Chirkov YY, Kennedy JA, et al. Inhibition of long-chain fatty acid metabolism does not affect platelet aggregation responses. Eur J Pharmacol. 1998;356(2–3):207–213.
   PubMed Web of Science ®Google Scholar
• Schmidt-Schweda S, Holubarsch C. First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci (Lond). 2000;99(1):27–35.
   PubMed Web of Science ®Google Scholar
• Turcani M, Rupp H. Modification of left ventricular hypertrophy by chronic etomixir treatment. Br J Pharmacol. 1999;126(2):501–507.
   PubMed Web of Science ®Google Scholar
• Cabrero A, Merlos M, Laguna JC, et al. Down-regulation of acyl-CoA oxidase gene expression and increased NF-kappaB activity in etomoxir-induced cardiac hypertrophy. J Lipid Res. 2003;44(2):388–398.
   PubMed Web of Science ®Google Scholar
• Gunther J, Wagner K, Theres H, et al. Myocardial contractility after infarction and carnitine palmitoyltransferase I inhibition in rats. Eur J Pharmacol. 2000;406(1):123–126.
   PubMed Web of Science ®Google Scholar
• Dhalla NS, Golfman L, Liu X, et al. Subcellular remodeling and heart dysfunction in cardiac hypertrophy due to pressure overload. Ann NY Acad Sci. 1999;874:100–110.
   PubMed Web of Science ®Google Scholar
• Sodi-Pallares D, Testelli MR, Fishleder BL, et al. Effects of an intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction. A preliminary clinical report. Am J Cardiol. 1962;9:166–181.
   PubMed Web of Science ®Google Scholar
• Kido Y, Nakae J, Accili D. Clinical review 125: the insulin receptor and its cellular targets. J Clin Endocrinol Metab. 2001;86(3):972–979.
   PubMed Web of Science ®Google Scholar
• Bonds DE. DIGAMI 1: 20 years later. Lancet Diabetes Endocrinol. 2014;2(8):603–604.
   PubMed Web of Science ®Google Scholar
• Malmberg K, Rydén L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol. 1995;26(1):57–65.
   PubMed Web of Science ®Google Scholar
• Worthley MI, Holmes AS, Willoughby SR, et al. The deleterious effects of hyperglycemia on platelet function in diabetic patients with acute coronary syndromes mediation by superoxide production, resolution with intensive insulin administration. J Am Coll Cardiol. 2007;49(3):304–310.
   PubMed Web of Science ®Google Scholar
• Mellbin LG, Malmberg K, Norhammar A, et al. Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 study. Diabetologia. 2011;54(6):1308–1317.
   PubMed Web of Science ®Google Scholar
• Jin PY, Zhang H-S, Guo X-Y, et al. Glucose-insulin-potassium therapy in patients with acute coronary syndrome: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2014;14:169.
   PubMed Web of Science ®Google Scholar
• Wargovich TJ, MacDonald RG, Hill JA, et al. Myocardial metabolic and hemodynamic effects of dichloroacetate in coronary artery disease. Am J Cardiol. 1988;61(1):65–70.
   PubMed Web of Science ®Google Scholar
• McVeigh JJ, Lopaschuk GD. Dichloroacetate stimulation of glucose oxidation improves recovery of ischemic rat hearts. Am J Physiol. 1990;259(4 Pt 2):H1079–85.
   PubMed Web of Science ®Google Scholar
• Wambolt RB, Lopaschuk GD, Brownsey RW, et al. Dichloroacetate improves postischemic function of hypertrophied rat hearts. J Am Coll Cardiol. 2000;36(4):1378–1385.
   PubMed Web of Science ®Google Scholar
• Stacpoole PW, Harman EM, Curry SH, et al. Treatment of lactic acidosis with dichloroacetate. N Engl J Med. 1983;309(7):390–396.
   PubMed Web of Science ®Google Scholar
• Stacpoole PW, Wright EC, Baumgartner TG, et al. A controlled clinical trial of dichloroacetate for treatment of lactic acidosis in adults. The dichloroacetate-lactic acidosis study group. N Engl J Med. 1992;327(22):1564–1569.
   PubMed Web of Science ®Google Scholar
• Kaufmann P, Engelstad K, Wei Y, et al. Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology. 2006;66(3):324–330.
   PubMed Web of Science ®Google Scholar
• Gilde AJ, Van Bilsen M. Peroxisome proliferator-activated receptors (PPARS): regulators of gene expression in heart and skeletal muscle. Acta Physiol Scand. 2003;178(4):425–434.
   PubMedGoogle Scholar
• Nikolaidis LA, Levine TB. Peroxisome proliferator activator receptors (PPAR), insulin resistance, and cardiomyopathy: friends or foes for the diabetic patient with heart failure? Cardiol Rev. 2004;12(3):158–170.
   PubMedGoogle Scholar
• Sharma AM, Staels B. Review: peroxisome proliferator-activated receptor gamma and adipose tissue–understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab. 2007;92(2):386–395.
   PubMed Web of Science ®Google Scholar
• Varas-Lorenzo C, Margulis AV, Pladevall M, et al. The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies. BMC Cardiovasc Disord. 2014;14:129.
   PubMed Web of Science ®Google Scholar
• Morita S, Mizuno Y, Harada E, et al. Pioglitazone, a peroxisome proliferator-activated receptor gamma activator, suppresses coronary spasm. Coron Artery Dis. 2014;25(8):671–677.
   PubMed Web of Science ®Google Scholar
• Asakawa M, Takano H, Nagai T, et al. Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation. 2002;105(10):1240–1246.
   PubMed Web of Science ®Google Scholar
• Noman A, Ang DSC, Ogston S, et al. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet. 2010;375(9732):2161–2167.
   PubMed Web of Science ®Google Scholar
• Saugstad OD. Role of xanthine oxidase and its inhibitor in hypoxia: reoxygenation injury. Pediatrics. 1996;98(1):103–107.
   PubMed Web of Science ®Google Scholar
• Rajaratnam R, Brieger DB, Hawkins R, et al. Attenuation of anti-ischemic efficacy during chronic therapy with nicorandil in patients with stable angina pectoris. Am J Cardiol. 1999;83(7):1120–4, A9.
   PubMed Web of Science ®Google Scholar
• Group IS. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet. 2002;359(9314):1269–1275.
   PubMed Web of Science ®Google Scholar
• Belsey J, Savelieva I, Mugelli A, et al. Relative efficacy of antianginal drugs used as add-on therapy in patients with stable angina: a systematic review and meta-analysis. Eur J Prev Cardiol. 2015;22(7):837–848.
   PubMed Web of Science ®Google Scholar
• Chen J, Cha-Molstad H, Szabo A, et al. Diabetes induces and calcium channel blockers prevent cardiac expression of proapoptotic thioredoxin-interacting protein. Am J Physiol Endocrinol Metab. 2009;296(5):E1133–9.
   PubMed Web of Science ®Google Scholar
• Park SY, Shi X, Pang J, et al. Thioredoxin-interacting protein mediates sustained VEGFR2 signaling in endothelial cells required for angiogenesis. Arterioscler Thromb Vasc Biol. 2013;33(4):737–743.
   PubMed Web of Science ®Google Scholar
• Vicari RM, Chaitman B, Keefe D, et al. Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial. J Am Coll Cardiol. 2005;46(10):1803–1811.
   PubMed Web of Science ®Google Scholar
• Ussher JR, Lopaschuk GD. Targeting malonyl CoA inhibition of mitochondrial fatty acid uptake as an approach to treat cardiac ischemia/reperfusion. Basic Res Cardiol. 2009;104(2):203–210.
   PubMed Web of Science ®Google Scholar
• Stanley WC, Morgan EE, Huang H, et al. Malonyl-CoA decarboxylase inhibition suppresses fatty acid oxidation and reduces lactate production during demand-induced ischemia. Am J Physiol Heart Circ Physiol. 2005;289(6):H2304–9.
   PubMed Web of Science ®Google Scholar
• Samokhvalov V, Ussher JR, Fillmore N, et al. Inhibition of malonyl-CoA decarboxylase reduces the inflammatory response associated with insulin resistance. Am J Physiol Endocrinol Metab. 2012;303(12):E1459–68.
   PubMed Web of Science ®Google Scholar
• Ritchie RH, Zeitz CJ, Wuttke RD, et al. Attenuation of the negative inotropic effects of metoprolol at short cycle lengths in humanscomparison with sotalol and verapamil. J Am Coll Cardiol. 2006;48(6):1234–1241.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. New Engl J Med. 2007;357(20):2001–2015.
   PubMed Web of Science ®Google Scholar
• Mohri M, Shimokawa H, Hirakawa Y, et al. Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm. J Am Coll Cardiol. 2003;41(1):15–19.
   PubMed Web of Science ®Google Scholar
• Kim, J.H, Shin ES, Lee JH, et al. A randomized multicenter double-blind placebo-controlled trial to evaluate the efficacy and safety of cilostazol in patients with vasospastic angina (STELLA trial). Eur Heart J. 2014;34(suppl 1): 648–649.
   Google Scholar
• Yoo S-Y, Song S-G, Lee J-H, et al. Efficacy of cilostazol on uncontrolled coronary vasospastic angina: a pilot study. Cardiovascular Therapeutics. 2013;31(3):179–185.
   PubMed Web of Science ®Google Scholar
• Cole PL, Beamer AD, McGowan N, et al. Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent. Circulation. 1990;81(4):1260–1270.
   PubMed Web of Science ®Google Scholar
• Gutierrez JA, Karwatowska-Prokopczuk E, Murphy SA, et al. Effects of ranolazine in patients with chronic angina in patients with and without percutaneous coronary intervention for acute coronary syndrome: observations from the MERLIN-TIMI 36 trial. Clin Cardiol. 2015;38(8):469–475.
   PubMed Web of Science ®Google Scholar
• Marti Masso JF, Martí I, Carrera N, et al. Trimetazidine induces parkinsonism, gait disorders and tremor. Therapie. 2005;60(4):419–422.
   PubMed Web of Science ®Google Scholar
• Masmoudi K, Masson H, Gras V, et al. Extrapyramidal adverse drug reactions associated with trimetazidine: a series of 21 cases. Fundam Clin Pharmacol. 2012;26(2):198–203.
   PubMed Web of Science ®Google Scholar
• Bondon-Guitton E, Perez-Lloret S, Bagheri H, et al. Drug-induced parkinsonism: a review of 17 years’ experience in a regional pharmacovigilance center in France. Mov Disord. 2011;26(12):2226–2231.
   PubMed Web of Science ®Google Scholar
• Beltrame JF, Turner SP, Leslie SL, et al. The angiographic and clinical benefits of mibefradil in the coronary slow flow phenomenon. J Am Coll Cardiol. 2004;44(1):57–62.
   PubMed Web of Science ®Google Scholar
• Veronese ML, Gillen LP, Dorval EP, et al. Effect of mibefradil on CYP3A4 in vivo. J Clin Pharmacol. 2003;43(10):1091–1100.
   PubMed Web of Science ®Google Scholar